Table 2.
Adverse event rates with odds ratios (OR) and 95% confidence intervals (CIs) between patients undergoing ERCP with or without pancreatic duct (P-duct) cannulation
| Adverse events |
|||||
|---|---|---|---|---|---|
| P-duct cannulation |
No P-duct cannulation |
||||
|
n = 9718 |
n = 33877 |
||||
| n | % | n | % | p | |
| Intraoperative | 402 | 4.1 | 848 | 2.5 | <0.0001 |
| Postoperative | 1645 | 16.9 | 4445 | 13.1 | <0.0001 |
| Pancreatitis | 764 | 7.9 | 877 | 2.6 | <0.0001 |
| Bleeding | 134 | 1.4 | 406 | 1.2 | 0.1563 |
| Adverse events |
|||||
| P-duct cannulation vs no cannulation |
|||||
| Unadjusted |
Adjusteda |
||||
| Odds ratio |
(95% CI) | Odds ratio | (95% CI) | p | |
| Intraoperative | 1.68 | (1.49–1.90) | 1.52 | (1.35–1.73) | <0.0001 |
| Postoperative | 1.35 | (1.27–1.43) | 1.44 | (1.35–1.54) | <0.0001 |
| Pancreatitis | 3.21 | (2.91–3.55) | 3.07 | (2.77–3.40) | <0.0001 |
| Bleeding | 1.15 | (0.94–1.40) | 1.12 | (0.91–1.37) | 0.2674 |
a
Adjusted for sex, age, ASA score, acute, indications, previous sphincterotomy. ERCP: endoscopic retrograde cholangio-pancreatography; ASA: American Society of Anesthesiologists.